| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | NAMS | Ordinary Shares | 19,878 | 29 Dec 2023 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | NAMS | Warrant (right to buy) | 29 Dec 2023 | Ordinary Shares | 44,619 | $11.50 | Direct | F2 | ||||||
| holding | NAMS | Option (right to buy) | 29 Dec 2023 | Ordinary Shares | 84,957 | $10.00 | Direct | F3, F4 | ||||||
| holding | NAMS | Option (right to buy) | 29 Dec 2023 | Ordinary Shares | 85,229 | Direct | F5, F6, F7 |
| Id | Content |
|---|---|
| F1 | This amendment is being filed to include 10,000 ordinary shares inadvertently omitted from the Form 3 filed by the Reporting Person on December 29, 2023. |
| F2 | This amendment is being filed to include warrants to purchase ordinary shares inadvertently omitted from the Form 3 filed by the Reporting Person on December 29, 2023. |
| F3 | The option was granted on November 22, 2022. The shares underlying the option vest in equal monthly installments over four years, with the first 1/48th of such shares vesting on December 1, 2022 and the remaining installments vesting on each one-month anniversary of the grant date, subject to the Reporting Person's continued service through each such date. 9,878 shares underlying the option have been exercised by the Reporting Person. |
| F4 | This amendment is being filed to remove options to purchase 9,878 ordinary shares inadvertently included in the Form 3 filed by the Reporting Person on December 29,2023. |
| F5 | The option was granted on November 22, 2022 to replace an option originally granted on July 8, 2021 which was cancelled in connection with the consummation of NewAmsterdam Pharma Company N.V.'s business combination with Frazier Lifesciences Acquisition Corporation. 25% of the shares underlying the option vested on June 1, 2022, the one-year anniversary of vesting start date, with the remaining shares vesting in equal monthly installments thereafter for three years, subject to the Reporting Person's continued service through each such date. |
| F6 | This amendment is being filed to include options to purchase 9,878 ordinary shares inadvertently omitted from the Form 3 filed by the Reporting Person on December 29, 2023. |
| F7 | The exercise price of the option is Euro 1.16392. |